Company Profile
Context Therapeutics Stock Price, News & Analysis
- Ticker:
- CNTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.50 USD (-27.27%)
Close
Last updated: August 6, 2026
222M USD
Market cap
Why the stock is moving
Following the latest company update, “Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress”, CNTX closed down 27.3% at $0.5040 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Solid-Tumor T-Cell Engagers
Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors.
CTIM-76
CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen.
CT-95
CT-95 is a mesothelin-directed CD3 bispecific antibody in Phase 1 development for mesothelin-expressing solid tumors.
CT-202
CT-202 targets Nectin-4 and CD3 and is preparing to enter first-in-human testing, adding a third tumor-associated antigen to the platform.
Future catalysts
Phase 1a interim data for CTIM-76 in June 2026.
Phase 1 initiation for CT-202 in the third quarter of 2026.
Phase 1a interim data for CT-95 in September 2026.
Recent news
- 01
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Source: Context Therapeutics
- 02
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: Context Therapeutics
- 03
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Source: Context Therapeutics
- 04
- 05
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
Source: Context Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Context Therapeutics (CNTX)?
Context Therapeutics (CNTX) most recently closed at 0.50 USD, a -27.27% move versus the previous session.
What is the market cap of Context Therapeutics (CNTX)?
Context Therapeutics currently has a market capitalization of 222M USD on BioPharmSignal.
What does Context Therapeutics do?
Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a mesothelin-directed CD3 bispecific...
On which exchange is CNTX stock listed?
Context Therapeutics (CNTX) is associated with NASDAQ, United States, Biopharma.
What is CTIM-76?
Phase 1a interim data for CTIM-76 in June 2026.
Which conditions is Context Therapeutics targeting with CTIM-76?
Phase 1a interim data for CTIM-76 in June 2026.
How does Context Therapeutics describe recent progress with CTIM-76?
Phase 1a interim data for CTIM-76 in June 2026.
What is CT-95?
CT-95 CT-95 is a mesothelin-directed CD3 bispecific antibody in Phase 1 development for mesothelin-expressing solid tumors.